Clinical trials: Immunomodulatory Drugs
Multiple Myeloma
A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Multiple myeloma (MM) is a neoplastic plasma cell disorder that is characterized by osteolytic bone lesions, anemia, hypercalcemia and renal failure.
- Trial name
- NCT04177823
- Testing
- Belantamab mafodotin
- Where
- China
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
Pancreas Cancer, Pancreatic Adenocarcinoma
Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer
A multi-center, open-label phase I/II study to to determine the safety and tolerability of Azacitidine and/or Romidepsin in combination with nab-Paclitaxel/Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma…
- Conditions
- Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- SEPION (NCT04257448)
- Testing
- Romidepsin, Azacitidine, nab-Paclitaxel
- Where
- 9 sites in Germany
- Volunteers
- 75 people
- Sponsor
- GWT-TUD GmbH
Membranous Nephropathy
Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy
Membranous Nephropathy (MN) is a renal autoimmune disease mediated by autoantibodies. Current management is based on the use of immunosuppressive therapies.
- Trial name
- ALPHAGEM (NCT05941845)
- Testing
- Peginterferon Alfa-2A 180 MCG/ML Injectable Solution
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Multiple Myeloma
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
This multicenter, open-label, Phase I study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab alone or in combination with daratumumab and/or various immunomodulatory agents in participants with MM who have…
- Trial name
- NCT02431208
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Daratumumab, Lenalidomide
- Where
- 31 sites in United States
- Volunteers
- 85 people
- Sponsor
- Hoffmann-La Roche
Influenza, Rheumatic Diseases
Vaccination Against Influenza H1N1 in Rheumatic Diseases
The spread of Influenza H1N1 has prompted the development of vaccines against this virus. Immunocompromised patients are at increased risk of developing complications of Influenza H1N1.
- Trial name
- NCT01006681
- Testing
- Focetria (Monovalent MF59-Adjuvanted vaccine)
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Relapsed/Refractory Multiple Myeloma
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.
To assess the safety and efficacy of CARTBCMA ARI0002h in patients with relapsed/refractory multiple myeloma who have received treatment with proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.
- Trial name
- NCT04309981
- Testing
- Adult differentiated autologous T-cells with anti-BCMA specificity
- Where
- 7 sites in Spain
- Volunteers
- 73 people
- Sponsor
- Sara V. Latorre
Multiple Myeloma
CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: Drugs such as CC-5013 and dexamethasone may be effective in treating primary systemic amyloidosis. PURPOSE: This phase II trial is studying CC-5013 to see how well it works with or without dexamethasone in treating…
- Trial name
- NCT00091260
- Testing
- dexamethasone, lenalidomide
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Vaishali Sanchorawala
Multiple Myeloma
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
Multiple myeloma (MM) is an incurable malignancy and accounts for 1 percentage (%) of all cancers and for 10% of all hematologic malignancies.
- Trial name
- NCT03525678
- Testing
- Belantamab mafodotin frozen liquid, Belantamab mafodotin lyophilized powder
- Where
- 59 sites in United States, Australia and 6 more
- Volunteers
- 221 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
Double-blind study will compare the efficacy and assess safety of selinexor plus carfilzomib (Kyprolis®) plus low-dose dexamethasone versus placebo plus carfilzomib plus low-dose dexamethasone in patients with relapsed/refractory…
- Trial name
- SCORE (NCT02628704)
- Testing
- Selinexor, carfilzomib, Dexamethasone
- Where
- 2 sites in United States
- Sponsor
- Karyopharm Therapeutics Inc
Immunomodulatory Drugs, Tuberculosis
Zinc and Selenium Bioactivity
The primary hypothesis of the study was that zinc and selenium supplementation through fortified cookies would enhance the immune response and improve clinical outcomes in tuberculosis patients.
- Trial name
- NCT07180329
- Testing
- Myrin P Fort, Zn + Se supplemented cookies, Zn + Se + Myrin P Fort
- Where
- Pakistan
- Volunteers
- 90 people
- Sponsor
- University of Lahore
Physiological Effects of Drugs
Immunomodulatory Effect of Dexmedetomidine as an Adjuvant Drug in Laparoscopic Cholecystectomies
Trauma triggers a tissue response involving the central nervous system, the hypothalamic-pituitary-adrenal axis and the immune system.
- Trial name
- NCT05489900
- Testing
- Dexmedetomidine Hydrochloride
- Where
- Brazil
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio de Janeiro
Relapse/Refractory Multiple Myeloma
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
This is an open-label, single-arm study of ATG-010 (selinexor) plus low-dose Dexamethasone (Sd) in patients with multiple myeloma previously treated with lenalidomide and bortezomib refractory to prior treatment with…
- Trial name
- MARCH (NCT03944057)
- Testing
- ATG-010
- Where
- 17 sites in China
- Volunteers
- 82 people
- Sponsor
- Antengene Corporation
Multiple Myeloma
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT03269136
- Testing
- PF-06863135 monotherapy IV or SC, PF-06863135 + dexamethasone, PF-06863135 + lenalidomide
- Where
- 37 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- Pfizer
Multiple Myeloma
Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs
The purpose of this study is to measure the incidence of hyperpigmentation in Black participants with multiple myeloma (MM) treated with immunomodulatory drugs (IMiDs) compared with Black participants with MM not treated with…
- Trial name
- NCT06160167
- Testing
- IMiD treatment, No IMiD treatment, Systemic therapy
- Where
- United States
- Volunteers
- 4,204 people
- Sponsor
- Bristol-Myers Squibb
Relapsing Polychondritis
Pragmatic, Open-Label Study to Pilot Evaluation for Clinical Trials in Relapsing Polychondritis
Open label pragmatic two-stage non-randomized trial comparing the effectiveness of five different standard of care treatment options for patients with relapsing polychondritis (RP).
- Trial name
- PROSECT RP (NCT06941376)
- Testing
- Methotrexate (MTX), Azathioprine (AZA), Adalimumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania
Multiple Myeloma
Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma
Elranatamab is a bispecific antibody: binding of elranatamab to CD3- expressing T-cell and BCMA- expressing multiple myeloma cells causes targeted T-cell mediated cytotoxicity.
- Trial name
- MAGNETISMM17 (NCT05462639)
- Testing
- Elranatamab (PF-06863135)
- Where
- 36 sites in United States, Canada
- Sponsor
- Pfizer
Immunomodulatory Drugs, Killer-cell Immunoglobulin-like Receptors (KIRs)
Effect of Immunomodulatory Treatment on IVF (in Vitro Fertilization) Outcomes in Patients With KIR AA Genotype
The aim of the study is to investigate the immune cause of recurrent implantation failure (RIF) and the role of immunomodulatory treatment in IVF (in vitro fertilization) patients that have a KIR AA genotype.
- Conditions
- Immunomodulatory Drugs, Killer-cell Immunoglobulin-like Receptors (KIRs), KIR Alleles (KIR AA)
- Trial name
- NCT06264206
- Testing
- Killer-cell immunoglobulin-like receptors (KIRs) testing
- Where
- Romania
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Calla IVF Center
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
This phase I/II trial identifies the best dose and side effects of selinexor, and how well it works when given in combination with pomalidomide and dexamethasone with or without carfilzomib in treating patients with multiple…
- Trial name
- NCT04764942
- Testing
- Carfilzomib, Dexamethasone, Pomalidomide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Mayo Clinic
Multiple Sclerosis
Cognitive Effects of Immunomodulatory Drugs in MS
The purpose of this study is to examine and compare changes in the specific thinking skills of patients with RRMS who are receiving treatment with one of three immunomodulatory medications (Avonex, Copaxone, or Rebif).
- Trial name
- NCT00229502
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Sharon Lynch, MD
High-risk Lung Nodules
Immunoprevention for High-risk Lung Lesions
The main purpose of this study is to assess nadunolimab as an immunoprevention strategy for high-risk lung nodules in participants who are current or former tobacco smokers. The study may last up to 5 years for each participant.
- Trial name
- NCT07284485
- Testing
- Nadunolimab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Robert Samstein